Review
Published on 14 Mar 2025
Insect-specific virus platforms for arbovirus vaccine development
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1521104
- 106 views
Type at least 3 characters
2,855 articles
Articles
Review
Published on 13 Mar 2025
Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1538301
- 136 views
Original Research
Published on 13 Mar 2025
Recombinant protein Ag85B-Rv2660c-MPT70 promotes quality of BCG-induced immune response against Mycobacterium tuberculosis H37Ra
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1430808
- 123 views
Brief Research Report
Published on 12 Mar 2025
The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1513175
- 269 views
Original Research
Published on 12 Mar 2025
BCG-derived acellular membrane vesicles elicit antimycobacterial immunity and innate immune memory
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1534615
- 225 views
Original Research
Accepted on 11 Mar 2025
Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1557426
Review
Accepted on 10 Mar 2025
Research progress of extracellular vesicles derived from mesenchymal stem cells in the treatment of neurodegenerative diseases
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1496304
Original Research
Accepted on 10 Mar 2025
Chimeric receptor-binding domain vaccine design and sequential immunization enhanced broadly neutralizing antibody responses against COVID-19
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1543212
- 133 views
Original Research
Accepted on 10 Mar 2025
Beyond interferon gamma -decreased cellular response to COVID-19 vaccination booster in patients with autoimmune inflammatory rheumatic diseases
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1568439
Original Research
Accepted on 07 Mar 2025
Improved antibody breadth with an extended primary dose interval of COVID-19 vaccine is overcome by boosters
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1529134
Review
Published on 07 Mar 2025
Current state of cancer immunity cycle: new strategies and challenges of using precision hydrogels to treat breast cancer
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1535464
- 289 views
Review
Published on 07 Mar 2025
Computational tools and data integration to accelerate vaccine development: challenges, opportunities, and future directions
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1502484
- 335 views
Original Research
Published on 07 Mar 2025
Screening and preclinical assessment of novel Mycobacterium tuberculosis recombinant antigens based tuberculin skin testing
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1498448
- 354 views
Original Research
Accepted on 06 Mar 2025
Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein-and Glycoprotein D-Based Vaccines Induce Local Tissue-Resident CD4 + and CD8 + TRM Cells Associated with Protection Against Recurrent Genital Herpes
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1568258
Original Research
Published on 06 Mar 2025
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1538453
- 532 views
Correction
Published on 06 Mar 2025
Corrigendum: Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus
in Vaccines and Molecular Therapeutics
Frontiers in Immunology
doi 10.3389/fimmu.2025.1566389
- 205 views